The bellwether trial will serve to determine if numerous lawsuits filed against generic drugmakers should be combined into a class-action case.
The lawsuits accuse the world’s top generic drugmakers of a conspiracy to fix, maintain and stabilize prices of generic drugs and engage in market and customer allocations of 200 generics.
The suits have been consolidated in a U.S. District Court for the Eastern District of Pennsylvania. They include antitrust suits from large healthcare companies, enforcement action by nearly every state attorney general and proposed class actions on behalf of drug distributors and retail pharmacies, according to Bloomberg Law.
Defendants had asked the court to use a lawsuit against Heritage Pharmaceuticals as a bellwether instead of Teva’s, arguing it is less complex and more manageable, but the judge Cynthia Rufe, denied that request.
More articles on pharmacy:
Moderna COVID-19 vaccine spurs immune response, initial data shows
Almost ‘like hurricane season’: Florida Walgreens pharmacy manager describes pandemic chaos
Sun Pharma faces retaliation lawsuit from former sales rep, its third in a year
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.